Eckerstein A, Slavin S, Weiss L, Naparstek E
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Bone Marrow Transplant. 1990 Jan;5 Suppl 1:38.
Although high-dose chemoradiotherapy used for conditioning prior to autologous bone marrow transplantation (BMT) represent an effective tool for eradication of certain malignant hematological disorders, relapses indicate that the last tumor cell is unlikely to be completely eradicated. We are investigating several approaches for controlling residual tumor cells escaping from chemoradiotherapy by cellular adoptive immunotherapy and amplification of natural defense mechanisms, using recombinant human IL2 (Cetus, Emeryville CA), in a murine model of leukemia/lymphoma disease (BCL1).
尽管用于自体骨髓移植（BMT）预处理的大剂量放化疗是根除某些恶性血液系统疾病的有效手段，但复发表明最后一个肿瘤细胞不太可能被完全根除。我们正在研究几种方法，通过细胞过继性免疫疗法以及利用重组人白细胞介素2（加州埃默里维尔市塞特斯公司生产）增强天然防御机制，在白血病/淋巴瘤疾病（BCL1）的小鼠模型中控制放化疗后逃逸的残留肿瘤细胞。
